Personalizing the Diuretic Treatment of Hypertension: the Need for More Clinical and Research Attention

Current Hypertension Reports

Volumn 17, Issue 4, 2015, Pages

  Mann, Samuel J ^a   Ernst, Michael E ^b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Chlorthalidone; Diuretics; Hydrochlorothiazide; Hypertension; Spironolactone; Torsemide

Indexed keywords

AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPITHELIAL SODIUM CHANNEL; EPLERENONE; ETACRYNIC ACID; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOOP DIURETIC AGENT; METOLAZONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM SPARING DIURETIC AGENT; SEROTONIN UPTAKE INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; TRIAMTERENE; POTASSIUM;

BLOOD PRESSURE REGULATION; CALCIUM BALANCE; CLINICAL RESEARCH; CREATININE BLOOD LEVEL; DIURETIC THERAPY; DRUG HALF LIFE; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; ERECTILE DYSFUNCTION; GOUT; GYNECOMASTIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; KIDNEY FUNCTION; MUSCLE CRAMP; PATIENT SELECTION; PERSONALIZED MEDICINE; PLASMA RENIN ACTIVITY; REVIEW; UREA NITROGEN BLOOD LEVEL; METABOLISM;

DIURETICS; EPITHELIAL SODIUM CHANNELS; HUMANS; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POTASSIUM; PRECISION MEDICINE;

EID: 84925353190     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-015-0542-4     Document Type: Review

References (80)

1. Arnett DK, Claas SA. Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance. Pharmacogenomics. 2009;10(8):1295–307.
2. Materson BJ. Insights into intrarenal sites and mechanisms of action of diuretic agents. Am Heart J. 1983;106(1 Pt 2):188–208.
3. Fernandez PC, Puschett JB. Proximal tubular actions of metolazone and chlorothiazide. Am J Physiol. 1973;225(4):954–61.
4. Paton RR, Kane RE. Long-term diuretic therapy with metolazone of renal failure and the nephrotic syndrome. J Clin Pharmacol. 1977;17(4):243–51.
5. Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJG, Phillips BB, Zimmerman MB, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47(3):352–8.
6. Messerli FH, Makani H, Benjo A, Romero J, Alviar C, Bangalore S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol. 2011;57:590–600. This meta-analysis demonstrates the prominent dose–response relationship for hydrochlorothiazide, with the relatively modest effect of the 25 mg dose as compared to other drugs.
7. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43(1):4–9.
8. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose–response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59(6):1104–9. This meta-analysis demonstrates how differences between these diuretics in achieved blood pressure are largely attributable to the dose prescribed rather than the drug per se.
9. Grimm RH, Leon AS, Hunninghake DB, Lenz K, Hannan P, Blackburn H. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med. 1981;94(1):7–11.
10. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59(6):1110–7. This meta-analysis suggests that chlorthalidone reduces cardiovascular endpoints more than hydrochlorothiazide does.
11. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57(4):689–94.
12. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Datab Syst Rev. 2009;3:CD001841.
13. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
14. Waeber B, Rotaru C, Feihl F. Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. Expert Opin Pharmacother. 2012;13(10):1515–26.
15. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16(11 Pt 1):925–30.
16. Jansen PM, Danser AHJ, Imholz BP, van den Meiracker AH. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009;27(4):680–91.
17. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31(4):153–8.
18. Swift PA, MacGregor GA. The epithelial sodium channel in hypertension: genetic heterogeneity and implications for treatment with amiloride. Am J Pharmacogenomics. 2004;4(3):161–8.
19. Saha C, Eckert GJ, Ambrosius WT, Chun TY, Wagner MA, Zhao Q, et al. Improvement of blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension. 2005;46(3):481–7.
20. Baker EH, Duggal A, Dong Y, Ireson NJ, Wood M, Markandu ND, et al. Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension. 2002;40(1):13–7.
21. Licht JH, Haley RJ, Pugh B, Lewis SB. Diuretic regimens in essential hypertension. A comparison of hypokalemic effects, BP control, and cost. Arch Intern Med. 1983;143(9):1694–9.
22. Setaro JF, Black HR. Refractory hypertension. N Engl J Med. 1992;327(8):543–7.
23. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39(5):982–8.
24. van Brummelen P, Schalekamp M, de Graeff J. Influence of sodium intake on hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin and aldosterone in essential hypertension. Acta Med Scand. 1978;204(3):151–7.
25. Erwteman TM, Nagelkerke N, Lubsen J, Koster M, Dunning AJ. Beta blockade, diuretics, and salt restriction for the management of mild hypertension: a randomised double blind trial. Br Med J (Clin Res Ed). 1984;289(6442):406–9.
26. Singer DR, Markandu ND, Sugden AL, Miller MA, MacGregor GA. Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide. Hypertension. 1991;17(6 Pt 1):798–803.
27. Mann SJ, Gerber LM. Estimation of 24-hour sodium excretion from spot urine samples. J Clin Hypertens (Greenwich). 2010;12(3):174–80.
28. Vaughan ED, Laragh JH, Gavras I, Bühler FR, Gavras H, Brunner HR, et al. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol. 1973;32(4):523–32.
29. Niarchos AP, Laragh JH. Effects of diuretic therapy in low-, normal- and high-renin isolated systolic systemic hypertension. Am J Cardiol. 1984;53(6):797–801.
30. Brooks CS, Johnson CA, Kotchen JM, Kotchen TA. Diuretic therapies in low renin and normal renin essential hypertension. Clin Pharmacol Ther. 1977;22(1):14–20.
31. Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH, Riehle JF, et al. Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009;22(7):792–801.
32. Khosla N, Chua DY, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich). 2005;7(6):354–6.
33. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008;2(6):462–8.
34. Kohvakka A, Eisalo A, Manninen V. Maintenance of potassium balance during diuretic therapy. Acta Med Scand. 1979;205(4):319–24.
35. BD, Lane DA. Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent. J Hypertens. 2007; [Online]. Available: http://ovidsp.tx.ovid.com/sp-3.13.0b/ovidweb.cgi?QS2=434f4e1a73d37e8cc073476c0173649e8203932b0dd05cfa175bb55163dbdec33213968f9c85955f6834399b6aeccdecc24279d7fdd2b71fe84a2ba8da0fbaffbd4c4ed7012f6df47df77bc7c6138436ba7a74cff1aa375d8bb957b2c8fe081cb8a3d6be835de0bf170c68835ebce8060bf402d3104daebc3c069e5bb030cf900a578211cdb34b8b12eaf017d8556f1219986cf4bf53f8761f07f44be28ab5f082447773de9779564a02255579b4a5e881d3f09fb74c5d25ee30404e00fbfff30ea10b7e204ce5fe59929ab68e521423acbe34e0b4b016e3e6d32a68d55abc6. [Accessed: 05-Sep-2014].
36. Agarwal R, Sinha AD. Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens. 5 Suppl 6:299–308.
37. Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol. 2014;39(2):171–82.
38. Wollam GL, Tarazi RC, Bravo EL, Dustan HP. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med. 1982;72(6):929–38.
39. Ram CV, Garrett BN, Kaplan NM. Moderate sodium restriction and various diuretics in the treatment of hypertension. Arch Intern Med. 1981;141(8):1015–9.
40. Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med. 2000;160(16):2429–36.
41. Ramsay LE, Boyle P, Ramsay MH. Factors influencing serum potassium in treated hypertension. Q J Med. 1977;46(184):401–10.
42. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;24 Suppl 265:3255–64.
43. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;23 Suppl 288:2981–29.
44. Mann SJ. The silent epidemic of thiazide-induced hyponatremia. J Clin Hypertens (Greenwich). 2008;10(6):477–84.
45. Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387–95.
46. Sunderam SG, Mankikar GD. Hyponatraemia in the elderly. Age Ageing. 1983;12(1):77–80.
47. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342(21):1581–9.
48. Smith SM, Anderson SD, Wen S, Gong Y, Turner ST, Cooper-Dehoff RM, et al. Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Pharmacotherapy. 2009;29(10):1157–65.
49. Garcá Puig J, Miranda ME, Mateos F, Herrero E, Lavilla P, Gil A. Hydrochlorothiazide versus spironolactone: long-term metabolic modifications in patients with essential hypertension. J Clin Pharmacol. 1991;31:455–61.
50. Falch DK, Schreiner A. The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives. Acta Med Scand. 1983;213(1):27–30.
51. Shafi T, Appel LJ, Miller ER, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension. 2008;52(6):1022–9.
52. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48(2):219–24.
53. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs. 1991;41(3):80–91.
54. McAdams DeMarco MA, Maynard JW, Baer AN, Gelber AC, Young JH, Alonso A, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. Arthritis Rheum. 2012;64(1):121–9.
55. Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case–control study. Arthritis Rheumatol (Hoboken, NJ). 2014;66(1):185–96.
56. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60(10):820–5.
57. Matsumura K, Arima H, Tominaga M, Ohtsubo T, Sasaguri T, Fujii K, et al. Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study. Clin Exp Hypertens. 2014;1–5.
58. Choi HK, Soriano LC, Zhang Y, Rodríguez LAG. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case–control study. BMJ. 2012;344:d8190.
59. Wasnich RD, Benfante RJ, Yano K, Heilbrun L, Vogel JM. Thiazide effect on the mineral content of bone. N Engl J Med. 1983;309:344–7.
60. LaCroix AZ, Wienpahl J, White LR, Wallace RB, Scherr PA, George LK, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med. 1990;322:286–90.
61. Leppla D, Browne R, Hill K, Pak CY. Effect of amiloride with or without hydrochlorothiazide on urinary calcium and saturation of calcium salts. J Clin Endocrinol Metab. 1983;57:920–4.
62. TRR, Mosenkis A. Muscle cramps and diuretic therapy. J Clin Hypertens (Greenwich, Conn). 2005;7:134–5.
63. Garrison SR, Dormuth CR, Morrow RL, Carney GA, Khan KM. Nocturnal leg cramps and prescription use that precedes them: a sequence symmetry analysis. Arch Intern Med. 2012;172(2):120–6.
64. Garrison SR, Allan GM, Sekhon RK, Musini VM, Khan KM. Magnesium for skeletal muscle cramps. Cochrane Datab Syst Rev. 2012;9:CD009402.
65. Katzberg HD, Khan AH, So YT. Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2010;74(8):691–6.
66. El-Tawil S, Al Musa T, Valli H, Lunn MP, El-Tawil T, Weber M. Quinine for muscle cramps. Cochrane Datab Syst Rev. 2010;8(12)CD005044. doi:10.1002/14651858.CD005044.pub2.
67. Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy S, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349(17):1628–35.
68. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28.
69. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290–300.
70. Bakris GL, Oparil S, Purkayastha D, Yadao AM, Alessi T, Sowers JR. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013;15(2):92–100.
71. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.
72. Cappuccio FP, Markandu ND, Singer DR, Buckley MG, Miller MA, Sagnella GA, et al. A double-blind crossover study of the effect of concomitant diuretic therapy in hypertensive patients treated with amlodipine. Am J Hypertens. 1991;4(4 Pt 1):297–302.
73. Cappuccio FP, Singer DR, MacGregor GA. The effects of thiazides plus calcium channel blockers. JAMA. 8 Suppl 264:971–3.
74. Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, Stewart WH. An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. JAMA. 1990;263(11):1507–12.
75. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52.
76. Brater DC. Clinical pharmacology of loop diuretics. Drugs. 1991;41(3):14–22.
77. Cosín J, Díez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4(4):507–13.
78. Bikdeli B, Strait KM, Dharmarajan K, Partovian C, Coca SG, Kim N, et al. Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives? J Am Coll Cardiol. 2013;61(14):1549–50. This meta-analysis suggests that chlorthalidone reduces cardiovascular endpoints more than hydrochlorothiazide does.
79. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther. 1993;7 Suppl 1:63–8.
80. Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995;49(1):121–42.